Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec;25(12):2183-2190.
doi: 10.3201/eid2512.190427.

Global Epidemiology of Buruli Ulcer, 2010-2017, and Analysis of 2014 WHO Programmatic Targets

Global Epidemiology of Buruli Ulcer, 2010-2017, and Analysis of 2014 WHO Programmatic Targets

Till F Omansen et al. Emerg Infect Dis. 2019 Dec.

Abstract

Buruli ulcer is a neglected tropical disease caused by Myocobacterium ulcerans; it manifests as a skin lesion, nodule, or ulcer that can be extensive and disabling. To assess the global burden and the progress on disease control, we analyzed epidemiologic data reported by countries to the World Health Organization during 2010-2017. During this period, 23,206 cases of Buruli ulcer were reported. Globally, cases declined to 2,217 in 2017, but local epidemics seem to arise, such as in Australia and Liberia. In 2013, the World Health Organization formulated 4 programmatic targets for Buruli ulcer that addressed PCR confirmation, occurrence of category III (extensive) lesions and ulcerative lesions, and movement limitation caused by the disease. In 2014, only the movement limitation goal was met, and in 2019, none are met, on a global average. Our findings support discussion on future Buruli ulcer policy and post-2020 programmatic targets.

Keywords: Australia; Benin; Buruli ulcer; Cameroon; Côte d’Ivoire; DRC; Democratic Republic of the Congo; Gabon; Ghana; Guinea; Japan; Liberia; Mycobacterium ulcerans; Nigeria; Papua New Guinea; Togo; World Health Organization; bacteria; epidemiology; programmatic targets; tuberculosis and other mycobacteria.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Typical Buruli ulcer lesion on the arm of a patient from Ghana. Central necrosis, yellowish-white slough, and undermined edges surround the wound. Photo courtesy of T.S. van der Werf.
Figure 2
Figure 2
Dynamics of Buruli ulcer epidemiology by cases reported to the World Health Organization (WHO) in 2010–2017. A) Globally, reported cases declined over time, but the proportion of cases reported from WPRO increased. B) WPRO data show an increase in cases in Australia. C) In AFRO, cases drastically declined in Côte d’Ivoire but recently increased in other countries such as Ghana, Nigeria, and Liberia. D) Countries in AFRO that reported fewer cases overall showed stagnant or varying numbers. AFRO, WHO African Region; WPRO, WHO Western Pacific Region.
Figure 3
Figure 3
Geographic distribution of Buruli ulcer cases officially reported to World Health Organization during 2010–2017. Concentrations in West Africa and Australia are clearly visible.
Figure 4
Figure 4
Depiction of progress toward World Health Organization programmatic targets for Buruli ulcer–endemic countries that reported continuous data. Black dotted lines indicate 2014 targets. White dots indicate that the country met the target; red dots indicate that it did not. Cat, category; +, positive.

References

    1. Yotsu RR, Suzuki K, Simmonds RE, Bedimo R, Ablordey A, Yeboah-Manu D, et al. Buruli ulcer: a review of the current knowledge. Curr Trop Med Rep. 2018;5:247–56. 10.1007/s40475-018-0166-2 - DOI - PMC - PubMed
    1. van der Werf TS, Stienstra Y, Johnson RC, Phillips R, Adjei O, Fleischer B, et al. Mycobacterium ulcerans disease. Bull World Health Organ. 2005;83:785–91. - PMC - PubMed
    1. Eddyani M, Sopoh GE, Ayelo G, Brun LVC, Roux J-J, Barogui Y, et al. Diagnostic accuracy of clinical and microbiological signs in patients with skin lesions resembling Buruli ulcer in an endemic region. Clin Infect Dis. 2018;67:827–34. 10.1093/cid/ciy197 - DOI - PMC - PubMed
    1. Einarsdottir T, Huygen K. Buruli ulcer. Hum Vaccin. 2011;7:1198–203. 10.4161/hv.7.11.17751 - DOI - PubMed
    1. Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, Phillips R, et al. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother. 2005;49:3182–6. 10.1128/AAC.49.8.3182-3186.2005 - DOI - PMC - PubMed

Publication types

LinkOut - more resources